Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8903862 | 0.91 | MAPT (0.46) | MAOBMAOASMN1; SMN2KMT2AACACB | |
| SCHEMBL12199929 | 0.90 | MAOA (0.50) | MAOBMAOARXRARXRBSMN1; SMN2 | |
| SCHEMBL8913414 | 0.89 | MAOA (0.43) | MAOBMAOASMN1; SMN2KMT2AACACB | |
| SCHEMBL8904961 | 0.88 | MAPT (0.46) | MAOBMAOASMN1; SMN2KMT2AMAPT | |
| SCHEMBL14773414 | 0.88 | MAOA (0.48) | MAOBMAOARXRARXRBSMN1; SMN2 | |
| SCHEMBL14770081 | 0.85 | MAOB (0.48) | MAOBRXRARXRBSMN1; SMN2GAA | |
| SCHEMBL14887050 | 0.82 | MAPT (0.48) | SMN1; SMN2KMT2ATP53ACACBMAPT | |
| SCHEMBL14884239 | 0.82 | GAA (0.39) | MAOBMAOASMN1; SMN2GAAKMT2A | |
| SCHEMBL15248785 | 0.82 | PRSS1 (0.42) | MAOBMAOASMN1; SMN2KMT2AMAPT | |
| SCHEMBL16603398 | 0.82 | MAOA (0.49) | MAOBMAOAKMT2AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8449953-B2 | Chiral dopants, liquid crystal matrix and manufacturing method thereof and liquid crystal display | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2013-05-28 | — | — | US | disclosed |
| US-8449953-B2 | Chiral dopants, liquid crystal matrix and manufacturing method thereof and liquid crystal display | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2013-05-28 | — | — | US | disclosed |
| US-20130063693-A1 | CHIRAL DOPANTS, LIQUID CRYSTAL MATRIX AND MANUFACTURING METHOD THEREOF AND LIQUID CRYSTAL DISPLAY | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2013-03-14 | — | — | US | disclosed |
| US-5656198-A | DISPLAY DEVICE | CITIZEN WATCH CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130063693-A1 | CHIRAL DOPANTS, LIQUID CRYSTAL MATRIX AND MANUFACTURING METHOD THEREOF AND LIQUID CRYSTAL DISPLAY | CNPY2, YBX3, CCR3 | MAOB 607/4885MAOA 756/4885RXRA 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.